Recombinant MT-ND3 refers to the Balaenoptera musculus (blue whale) NADH dehydrogenase subunit 3 protein synthesized using recombinant DNA technology. It is a hydrophobic transmembrane protein critical for the catalytic activity of mitochondrial complex I (NADH:ubiquinone oxidoreductase), which transfers electrons from NADH to ubiquinone while pumping protons across the mitochondrial inner membrane .
Produced in E. coli with an N-terminal His-tag for affinity chromatography .
Lyophilized for long-term storage, reconstituted in Tris/PBS buffer with glycerol .
Antibody Production: Used as an immunogen for generating polyclonal antibodies (e.g., ab204977) .
Enzyme Activity Studies: Investigates complex I dysfunction in mitochondrial diseases .
Structural Biology: Supports crystallography or cryo-EM studies of respiratory chain complexes .
Disease Associations: Mutations in MT-ND3 are linked to mitochondrial disorders such as Leigh syndrome (LS) and Leber’s hereditary optic neuropathy (LHON) . For example, the A47T substitution (10197G>A mutation) disrupts complex I assembly and reduces catalytic activity by ~70% .
Therapeutic Target: Recombinant ND3 enables functional rescue studies in cell models of mitochondrial disease .